Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesothelioma Stratified Therapy (MiST)
2017-003353-41Phase 2Unknown
- Sponsor
- University of Leicester
- Start
- Jul 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, olaparib, abemaciclib, atezolizumab, bevacizumab and 3 more in pleural mesothelioma and peritoneal mesothelioma (6 arms), sponsored by University of Leicester. Primary endpoint: 12-week disease control rate. Status: unknown.
02
Drugs
03
Conditions
pleural mesotheliomaperitoneal mesothelioma
Beyond the preview
Go deeper on 2017-003353-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003353-41.